<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="88980">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01829152</url>
  </required_header>
  <id_info>
    <org_study_id>SARHF-0319</org_study_id>
    <nct_id>NCT01829152</nct_id>
  </id_info>
  <brief_title>Verizon Wireless - Sarasota Memorial Hospital Converged Health Management (CHM) For Heart Failure</brief_title>
  <official_title>Verizon Wireless - Sarasota Memorial Hospital Converged Health Management (CHM) For Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verizon Wireless</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verizon Wireless</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the impact on heart failure related quality of life
      when integrating a mobile health system, Verizon Wireless's Converged Health Management
      (CHM), into a subject's self-management of their heart failure (HF) as well as in the
      medical management of HF by the subjects' clinical team.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening</study_design>
  <primary_outcome>
    <measure>Quality of life, as measured by subject response to the Minnesota Living with Heart Failure Questionnaire (MLWHF).</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the impact of the CHM intervention on the subjects' medication adherence as gathered from the Morisky Medication Adherence questionnaire.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects in the Control Group will receive Heart Failure care as routinely delivered by the SMH HF clinicians according to their standards of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHM Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Intervention Group subjects will receive Converged Health Management (CHM) in addition to continuing to receive care as routinely delivered by the SMH HF clinicians.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CHM</intervention_name>
    <arm_group_label>CHM Intervention Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult (â‰¥ 18 years of age)

          2. A least 1 prior hospitalization within the past 12 months for HF based upon the
             presence of at least 1 symptom (dyspnea, orthopnea, or edema) AND at least 1 sign
             (rales, peripheral edema, ascites, or pulmonary vascular congestion on chest
             radiography)AND treatment with a loop diuretic during the hospital stay OR Symptoms
             of New York Hospital Association (NYHA) Class 2+ symptoms:  dyspnea, fatigue, or
             chest pain with normal physical activity (class II), less than ordinary activity
             (class III) or at rest (class IV).

             Information may be provided by subject self-report obtained during the initial
             screening process and/or by medical record confirmation.  Compliance with all
             eligibility criteria will be confirmed at the initial study visit before subject is
             presented with the ICF.

          3. Receiving care at the SMH HF Clinic and assessed by the clinic at least twice.
             (Those who were seen in person on their first visit and then followed-up by telephone
             thereafter will be considered eligible).

          4. Able to provide contact information for someone who agrees to provide information
             about the subject if the subject is not available to do so.

          5. Capability of understanding and willingness to comply with the protocol and study
             requirements, assessed according to the Principal Investigator's judgment.

          6. Ability to understand and willingness to sign a written informed consent document,
             assessed according to the Principal Investigator's judgment.

        Exclusion Criteria:

          1. Decline to participate in the study

          2. Reside in an area with limited to no Verizon Wireless coverage as determined by VZ
             using the VZ zip code coverage analysis technology.

          3. Scheduled procedure for left ventricular device implantation, or listed for potential
             cardiac transplant

          4. Current resident of a long-term care or skilled nursing facility

          5. Currently receiving palliative or hospice care

          6. Human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS)
             based on past medical history or subject self-report

          7. Dialysis-dependent, end-stage renal disease

          8. A concurrent physical condition (including rare or chronic diseases such as sickle
             cell anemia or cystic fibrosis) or mental health condition (including dementia,
             schizophrenia, or other mental illness) that in the view of the Principal
             Investigator would compromise the subject's ability to fulfill the protocol
             requirements or affect the subject's safety during the study

          9. Are unable or unwilling to comply with the study requirements as instructed including
             coming to the SMH HF clinic for the 2 study visits.

         10. For subjects in the Intervention Group that are:

               1. Unable or unwilling to return to the SMH clinic to receive their     training,
                  devices and study material after signing the informed consent form and being
                  randomized into the Intervention Group;

               2. Unable or unwilling to use the biometric devices and CHM at least one time per
                  day.

         11. Are pregnant or planning to become pregnant during the study.

             -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirk Voelker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sarasota Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sarasota Memorial Hospital Heart Failure Clinic</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Grimes</last_name>
      <email>james-grimes@smh.com</email>
    </contact>
    <contact_backup>
      <last_name>Nancy Clapp</last_name>
      <email>nancy-clapp@verizonwireless.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kirk Voelker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 31, 2014</lastchanged_date>
  <firstreceived_date>April 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
